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Abstract
Objectives. The role of tumor-associated neutrophils (TANs) in the
nodal spread of cancer cells remains unexplored. The present
study evaluates the occurrence and clinical signiﬁcance of human
nodal TANs. Methods. The relevance, derivation, phenotype and
interactions of nodal TANs were explored via a large
immunohistochemical analysis of carcinoma-draining lymph nodes,
and their clinical signiﬁcance was evaluated on a retrospective
cohort of oral squamous cell carcinomas (OSCC). The tumorpromoting function of nodal TAN was probed in the OSCC TCGA
dataset combining TAN and epithelial-to-mesenchymal transition
(EMT) signatures. Results. The pan-carcinoma screening identiﬁed
a consistent inﬁltration (59%) of CD66b + TANs in tumor-draining
lymph nodes (TDLNs). Microscopic ﬁndings, including the
occurrence of intra-lymphatic conjugates of TANs and cancer cells,
indicate that TANs migrate through lymphatic vessels. In vitro
experiments revealed that OSCC cell lines sustain neutrophil
viability and activation via release of GM-CSF. Moreover, by
retrospective analysis, a high CD66b + TAN density in M-TDLNs of
OSCC (n = 182 patients) predicted a worse prognosis. The analysis
of the OSCC-TCGA dataset unveiled that the expression of a set of
neutrophil-speciﬁc genes in the primary tumor (PT) is highly
associated with an EMT signature, which predicts nodal spread.
Accordingly, in the PT of OSCC cases, CD66b+TANs co-localised
with PDPN+S100A9 EMT-switched tumor cells in areas of
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lymphangiogenesis. The pro-EMT signature is lacking in peripheral
blood neutrophils from OSCC patients, suggesting tissue skewing
of TANs. Conclusion. Our ﬁndings are consistent with a novel protumoral TAN compartment that may promote nodal spread via
EMT, through the lymphatics.
Keywords: carcinoma, epithelial-to-mesenchymal transition, lymph
nodes, metastasis, tumor-associated neutrophils

Tumor-associated myeloid cells encompass a large
variety of circulating and tissue cellular
components at various stages of differentiation.
Among them, tumor-associated macrophages,
dendritic cells and neutrophils represent the most
well-characterised cell populations. 1–3 As a group,
tumor-associated myeloid cells exert pro-tumor
functions, but recent data have challenged this
view, suggesting an extreme plasticity of these
cells modulated by the tumor microenvironment
at various disease stages. 4
5
Emergency granulopoiesis is prominent in latestage cancer and mostly accounts for the high
neutrophil count and the altered neutrophil-tolymphocyte ratio (NLR) in advanced stages. Within
the expanded granulocyte compartment, various
subpopulations have been identiﬁed based on
their ontogeny, fraction in the density gradient
separation, phenotype and function.5–7 Among
the circulating neutrophils, immunosuppressive
low-density neutrophils (LDNs), known as
polymorphonuclear myeloid-derived suppressor
cells (PMN-MDSCs), have recently gained great
attention.7 An additional granulocyte population
is represented by neutrophils found within the
tumor tissues, the so-called tumor-associated
neutrophils (TANs).8 Their connection with LDNs/
PMN-MDSCs and normal circulating neutrophils
still remains unclear due to the lack of speciﬁc
markers.
Similarly
to
tumor-associated
macrophages,2 TANs can be polarised in vitro.9,10
N1-type TANs, induced by type I IFN, mainly exert
anti-tumoral functions10 and promote cancer cell
elimination. On the contrary, N2-type TANs are
TGF-b-driven and sustain tumor cell proliferation,
angiogenesis, invasion, metastasis and immune
escape.8,9,11 Data on TAN polarisation are limited
to murine models, and it is still unknown whether
human TANs display similar polarisation. Most of
the studies performed in retrospective cancer
cohorts12 have supported a pro-tumor function of
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TANs, with a high TAN tumor density signiﬁcantly
13
associated with a worse outcome. Although this
ﬁnding supports a dominant N2 polarisation of
TANs in human cancer, emerging data have
revealed extreme plasticity of these cells.
Speciﬁcally, when puriﬁed from early-stage
cancers, TANs exert anti-tumor activities and
display a hybrid phenotype together with
antigen-presenting cell features.14,15
Data on the biological and clinical signiﬁcance
of TANs have been obtained with the leading
assumption that they execute their programs at
the primary tumor (PT) site or in distant
metastasis and largely ignoring their role in the
tumor-draining lymph nodes (TDLNs). Nodal
colonisation by cancer cells is a harbinger of
systemic tumor spread and this is clinically
relevant in a signiﬁcant fraction of cancer types.16
In addition, TDLNs are crucial sites for the
organisation of the immune response to tumor
antigens. A signiﬁcant component of the tumorpromoting activity of LDNs/PMN-MDSCs and TANs
derives from their negative modulation of the
anti-tumor T-cell response. 5,7,8 Recent studies in
mouse models have shown that neutrophil entry
into the node results in a potent negative
regulation of the speciﬁc T-cell response to
pathogens.17–19 However, very limited data are
available on the identiﬁcation of nodal TANs and
their characterisation during cancer evolution in
humans.
Herein, by performing a screening of human
cancer tissues including PTs and TDLNs, we
identiﬁed that high CD66b+ TAN density is
common in TDLNs from various primary sites.
CD66b+ TANs in TDLNs co-express classical
neutrophil markers, as well as the recently
identiﬁed markers of PMN-MDSCs such as
S100A9,20 arginase-1, pSTAT3 and c/EBPb.21 Our
data support the notion that TANs could enter
the TDLN via lymphatic vessels, forming
intraluminal conjugates with cancer cells. The
preferential TAN interplay with cancer cells has
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RESULTS
CD66b+ TANs recurrently accumulate in
carcinoma-draining lymph nodes
A large number of studies have documented the
clinical relevance of TANs inﬁltrating the primary
tumor (PT) site and distant metastasis. 9,13 We
recently observed that CD66b+ TANs are also
found in metastatic tumor-draining lymph nodes
(M-TDLNs) from patients with colon carcinomas. 27
To further follow up this ﬁnding, we extended
our characterisation to a larger cohort of cancer
patients. Compared to other myeloid markers,
CD66b is selectively expressed by granulocytes.
Clone G10F5 is suitable for staining on FFPE
sections and, among immune cells, it is selectively
restricted to mature neutrophils, as demonstrated
by the analysis of primary (n = 6) and secondary
(n = 30)
lymphoid
organs
(Supplementary
ﬁgure 1a– h). In inﬂamed lymph nodes from nontumor-bearing hosts (n = 21), CD66b+ neutrophils
are generally scant and limited to the HEV dilated
lumen (Supplementary ﬁgure 1e) with the
exception
of
suppurative
necrotising
lymphadenitis of
infectious origin
(n = 3;
Supplementary ﬁgure 1f). By using archival
material, we analysed a total of 278 M-TDLNs of
carcinomas
from
various
primary
sites
(Supplementary
table 1).
Nodal
localisation
of CD66b+ TANs was observed in 59% of M-TDLNs
(n = 165/278). Based on a three-tiered scoring
system (score 0, 1 and 2; illustrated in
Supplementary ﬁgure 2 and detailed in the
Methods), CD66b+ TAN inﬁltration was highly
dense (score 2) in 31.5% of the M-TDLNs ( n = 52/

165) from various primary sites and with different
histologies (Figure 1a, Supplementary ﬁgure 2
and Supplementary table 1). Dense CD66b+ TAN
inﬁltration was common in head and neck
squamous cell carcinomas, adenocarcinomas of
the gastrointestinal tract, of the pancreas, of the
thyroid and ovary, as well as in urothelial bladder
cancer. On the contrary, CD66b+ TANs were rarely
observed in breast carcinoma (Supplementary
table 1 and Figure 1a). We extended the latter
ﬁnding on breast carcinoma to an additional
cohort (n = 38) and compared concurrently
removed M-TDLNs and PT (n = 22). A low CD66b+
TAN density was conﬁrmed in the majority of the
cases including in the PTs (Supplementary
ﬁgure 2i, j).
In term of nodal localisation (Figure 1b–f and
Supplementary ﬁgure 3), CD66b+ TANs in M-TDLNs
were localised within and immediately around the
metastatic deposits (M-TDLNM ) (n = 100/165; 60.6%
CI95% 52.7–68.1%) (Figure 1b and d green asterisks).
They were also present in the remaining spared nodal
parenchyma (M-TDLNP), where they were located
mainly within the lumen of marginal, intermediate
and medullary lymphatic sinuses (n = 90/165; 54.5%
CI95% 46.6–62.3%; Figure 1b, c and e red asterisks).
The identity of the expanded lymphatic sinuses was
conﬁrmed by using a set of endothelial cell markers
including podoplanin, CD31, Lyve-1, CD34, ERG,
Factor VIII, and CLA/HECA 452 (Figure 1f,
Supplementary ﬁgure 4a–e) in M-TDLNs cases
(n = 10). CD66b+ TANs frequently engulfed some
dilated HEVs (Supplementary ﬁgure 4f). However, as
evaluated by double immunohistochemistry, CD66b+
TANs were only rarely observed as transmigrating
cells
(Supplementary
ﬁgure 4g)
or
closely
surrounding HEV (n = 10).
The expression of a panel of neutrophil-speciﬁc
molecules suitable for archival tissue was analysed
in a set of M-TDLNs and matched PTs (n = 9).
CD66b+ TANs showed a segmented nucleus and
co-expressed
CD11b,
CD10,
CD16,
myeloperoxidase,
neutrophil
elastase
and
cytoplasmic
granule-associated
molecules
conﬁrming their neutrophil identity and mature
phenotype (Supplementary ﬁgure 5a–j).

CD66b+ TANs engulf lymphatic vessels of
the PTs and predict the TDLN colonisation of
cancer cells
Recently, by using murine models, a number of
studies have shown that neutrophils can also
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recently been reported including in squamous cell
carcinomas (SCC).22–25 By the analysis of a
retrospective cohort, colonisation of carcinomadraining lymph nodes by TANs predicts poor
outcome in advanced oral squamous cell cancer
(OSCC). Accordingly, increased CD66b+ TAN
density correlated with recurrent head and neck
SCC. By in silico evaluation of the OSCC TCGA
dataset, we found that expression of a set of
neutrophil-speciﬁc genes at the PT is associated
with an epithelial-to-mesenchymal transition
(EMT) signature, the latter known to predict
nodal spread in OSCC.26 These ﬁndings highlight a
hitherto unrecognised contribution of TANs in
nodal colonisation by modulating EMT-dependent
lymphatic spread.

Tumor-associated neutrophils in human carcinoma-draining lymph nodes

(a)

(e)

(c)

(f)

Figure 1. CD66b+ TAN density and localisation in M-TDLN. (a) The density of CD66b+ TANs expressed as TAN score (S0 = white, S1 = grey,
S2 = black; three-tiered score is reported in the Methods section) in 278 M-TDLNs obtained from various primary carcinomas. (b) The distribution
of CD66b + TANs in different LN compartments (red asterisks indicate marginal, intermediate sinuses and medullary sinuses whereas green
asterisks indicate CD66b + cells within and around the metastatic nest). (c) The density of CD66b + TANs localised in the metastatic nest (MTDLNM , black column) and in the surrounding nodal parenchyma (M-TDLNP , white column). Sections are from cases of M-TDLN of colon
carcinoma (d) and head and neck squamous cell carcinoma (e, f), stained as labelled (CK = cytokeratin 7) and illustrating CD66b + TANs within
and around ( d, green asterisks) the metastatic nests, within marginal and intermediate sinuses (e, red asterisk and f). In f, lymphatic sinuses are
identiﬁed by positivity for podoplanin. Sections are counterstained with haematoxylin. Original magniﬁcation: 409 (e, scale bar 500 lm), 1009
(d, f , scale bar 200 lm), 4009 (inset in d), 6009 (inset in f). GC, germinal centre.

trafﬁc through the lymph in response to
pathogens,17,18,28 raising the possibility that
neutrophils modulate adaptive immunity directly
within the lymph node.29 Our data on the
localisation of CD66b+ TANs in nodal sinuses of
TDLNs strongly support their migration from the
primary tumor site through the lymphatic system.
This hypothesis is further strengthened by a set of
indirect ﬁndings. First, CD66b + TANs from MTDLNs are negative for active caspase-3 (n = 10)
and ki-67 (Figure 2a–d) (n = 13), indicating that
the CD66b+ TAN pool is less susceptible to
spontaneous apoptosis and independent from
local self-renewal, as other tumor-associated
innate components. 30 Moreover, by comparative
analysis of PTs and matched M-TDLNs (n = 45), we
found a high correlation (Spearman r = 0.77;
P < 0.0001) between CD66b + TAN density scores
(Supplementary ﬁgure 2g–l). Finally, as observed
by double immunohistochemistry on serial
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sections of M-TDLNs (n = 4), CD66b + TANs in the
PTs were often detected within enlarged
lymphatic vessels in the form of multicellular
tumor emboli admixed with carcinoma cells
(Figure 2e and f), T cells (Figure 2g) and
macrophages
(Figure 2h).
Remarkably,
this
multicellular interaction was not limited to the PT
lymphatic vessels, but was also detectable within
the marginal sinuses of M-TDLNs (Figure 2i; n = 5).
TAN migration via lymphatics requires endothelial
activation
for
adhesion,
integrin-mediated
binding through ICAM-1 and VCAM-1 and CXCL8dependent chemotaxis.31–33 We found that CXCL8
is expressed in PT cases (n = 5) with massive
CD66b+ TAN embolisation (Figure 2j and k), with
the main cellular source represented by the
CD66b+ TANs themselves (Figure 2j and inset);
CXCL8+ CD66b+ TANs were also detected in
lymphatic sinuses of M-TDLNs (Figure 2l). Since
TANs and tumor cells share their path to TDLNs, it
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CD66b+ TAN immune-contexture in
squamous cell carcinoma of the oral cavity
(OSCC)
In our screening cohort, CD66b+ TAN inﬁltration
in TDLNs was striking in head and neck squamous
cell carcinoma (Figure 1a, Supplementary table 1).
By co-culture experiments combining circulating
neutrophils with three human OSCC lines, we
found that OSCC cells provide a signiﬁcant
survival signal to neutrophils as measured by
Vibrant dye assay (Figure 3a and Supplementary
ﬁgure 6). A similar response, albeit attenuated,
was seen with exposure of neutrophils to OSCCderived supernatants (Figure 3b), which also
induced neutrophil activation as revealed by
membrane up-regulation of CD11b (Figure 3c)
and down-regulation of CD62L (Figure 3d). By
ELISA and blockade experiments, we found these
effects were mostly dependent on GM-CSF, but
not IL-6, released by OSCC cells (Figure 3b–e). To
establish the clinical signiﬁcance of CD66b+ TAN
inﬁltration, we measured CD66b+ TAN density in a
large retrospective cohort of OSCC (n = 182). We
identiﬁed OSCC patients who underwent radical
surgery of the PT with node dissection. Clinical
details of the cohort are reported in
Supplementary tables 2 and 4. A representative
tissue block of the PT and at least one block
containing multiple TDLNs were available for the
analysis. For N+ patients (≥ Stage III AJCC), MTDLNs were included (Supplementary ﬁgure 7).
Data and representative images are shown in

Figure 3,
Supplementary
ﬁgure 8
and
Supplementary tables 2 and 3. In the PT, we
analysed a mean tumor area of 105  71 mm2.
The median density of CD66b+ TANs was 175 cells
mm2, and it was signiﬁcantly higher in the
invasive margin (IM) compared to the centre of
the tumor (CT) (194 cells mm2 vs 155 cells mm2 ;
P < 0.0001; Supplementary table 4, Figure 3f).
We subsequently tested CD66b + TAN density in
TDLNs by analysing M-TDLNs (n = 219), and NMTDLNs (n = 626). For M-TDLNs, counts were also
performed in the two distinct compartments, the
metastatic nest (M-TDLN M) and the surrounding
P
nodal parenchyma (M-TDLN ), the latter mainly
+
accounting for CD66b TANs within the lymphatic
sinuses. TAN density in the PT showed a strong
direct correlation with TAN density in TDLNs,
particularly in the M-TDLNs (r = 0.5; P < 0.001;
Figure 3g, Supplementary table 4). Remarkably,
the strongest correlation between sub-regions was
observed between the CT of the PT and the MTDLNM (Spearman r = 0.49, P < 0.001; Figure 3g),
consistent with CT CD66b+ TANs receiving an
appropriate imprinting signal(s) to establish a
nodal pre-metastatic niche.

Clinical signiﬁcance of TAN immunecontexture in OSCC compartments
Data on the prognostic signiﬁcance of TAN density
in human cancer are still inconclusive. We tested
the clinical relevance of CD66b+ TAN density in PTs
and TDLNs. Univariate analysis of clinicalpathologic prognosticators for overall survival (OS)
conﬁrms that T stage, AJCC stage, nodal status and
lympho-vascular
invasion
represented
the
strongest prognostic factors (Supplementary
table 2). In particular and as previously
recognised,37 the occurrence of extracapsular
spread (ECS) resulted in a striking decrease of
survival estimates in patients with nodal
metastasis. Moreover, the multivariable analysis
conﬁrmed nodal status as the most powerful
independent
prognosticator
(Supplementary
table 2). We then tested the prognostic
signiﬁcance of CD66b+ TAN, as continuous
variable, by performing a multivariable analysis
including interaction terms in the model. Of note,
when measured in the entire tumor area, the
CD66b+ TAN density was not signiﬁcantly
associated with prognosis. However, CD66b+ TAN
densities measured at the CT or at the IM were
predictive of survival (P = 0.019 and P = 0.033,
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is conceivable that TANs contribute to organising
the pre-metastatic niche, as previously proposed
for distant metastasis.3,34 We thus extended our
analysis to 175 non-metastatic TDLNs (NM-TDLNs,
Supplementary table 1). Notably, we also
observed nodal localisation of CD66b+ TANs in a
signiﬁcant fraction of the NM-TDLNs (77/175,
44.0% CI95% 36.5–51.7%). In terms of nodal
localisation in NM-TDLNs, high CD66b+ TAN
density was found within the lymphatic sinuses
(67/77, 87.0% CI 95% 77.4–93.6%; Supplementary
ﬁgures 3 and 4). Also, within the nodal sinuses,
CD66b+ TANs co-existed with numerous CD163+
macrophages and CD3+ lymphocytes (n = 5;
Supplementary ﬁgure 4h, i). These ﬁndings
suggest that multiple interactions of TANs within
the lymphatic sinuses might occur and may
establish a pre-metastatic niche in TDLNs similar
to distant sites.35,36
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(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

Figure 2. Lymphatic derivation of nodal CD66b + TANs. Sections of M-TDLNs (a-d, i, l) [from lung carcinoma (a–d) and gastric carcinoma (i, l)]
and of PT (e–h, j, k) [from gastric (e, f, k) and lung (g, h, j) carcinomas] stained as labelled. As illustrated by double stain, most of CD66b+
TANs from M-TDLNs are negative for active caspase-3 (a, b) and ki-67 (c, d) in both M-TDLN compartments (M-TDLNM [a, c]; M-TDLN P [b, d ]). In
primary carcinomas, CD66b+ TANs are found within podoplanin + lymphatic vessels (e, f) similarly to CD3+ T cells (g) and CD163 + macrophages
(h), frequently admixed to carcinoma cells (e–h); this ﬁnding is conﬁrmed in M-TDLN by a triple stain for podoplanin, CD66b and the carcinoma
cell marker claudin 4 (CL4) (i). Neoplastic cells (j) and TANs (inset in j, k and l) express CXCL8, also within lymphatic vessels (k, l). The latter
ﬁnding is observed in a primary gastric carcinoma (k) and in the corresponding M-TDLN (l). Sections are counterstained with haematoxylin.
Original magniﬁcation: 1009 (e, k, scale bar 200 lm), 2009 (g–i, l, scale bar 100 lm), 4009 (a, b, f, j, scale bar 50 lm), 6009 (c, d and inset
in j, scale bar 33 lm).

respectively; Table 1). Moreover, a signiﬁcant
interaction of the variables was identiﬁed with the
AJCC stage (P = 0.013 and P = 0.013, respectively;
Table 1). Speciﬁcally, a higher CD66b+ TAN density
in the IM associated with worse prognosis in early
stages I and II (H.R. 1.53, 0.87–2.71), whereas it
predicted a better outcome in advanced stages III
and IV (H.R. 0.42, 0.16–1.11; Figure 3h). By
contrast, a higher CD66b+ TAN density in the CT
associated with worse prognosis in advanced
stages III-IV (H.R. 1.59, 1.06–2.39) and with a better
outcome in earlier stages I-II (H.R. 0.42, 0.16–1.11;
Figure 3i and j).
Including M-TDLNs TAN densities, thus limiting
the analysis to N+ patients, a higher TAN density
in the M-TDLNM was associated with worse
prognosis (P = 0.004; Figure 3k and l), suggesting

2021 | Vol. 10 | e1252
Page 6

a pro-tumor function of nodal TANs. The
signiﬁcant interaction detected between M-TDLNs
TAN density and ECS status (P = 0.036) led to a
stronger effect of the M-TDLNs TAN density on
the outcome prediction in ECS positive patients
(H.R. 2.19, 1.28 –3.73) compared to ECS negative
ones (1.22, 1.00–1.48; Table 1, Figure 3l).
We further extended these analyses on the
clinical signiﬁcance of CD66b+ TANHi in the TDLNM
by identifying the appropriate cut-off of TAN
density at 163 cells mm2 (P = 0.07). Of note,
CD66b+ TANHi density in the M-TDLNM conﬁrms its
detrimental effect in terms of 5 year-OS (14%
CI95% 4–52%, vs 49% CI95% 37–63% Figure 3m).
Moreover, when the ECS was considered, the MTDLNM CD66b + TANHi / ECS+ group showed the
worst OS (2y-OS 17% CI95% 3–99%, 5y-OS:
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insufﬁcient patients at risk) followed by the MTDLN M CD66b+ TAN Hi / ECS (5y-OS 25% CI 95% 8–
83%) and M-TDLNM CD66b + TAN Lo/ECS+ (33%
CI95% 19–55%) groups. The 5y-OS in the M-TDLNM

CD66b+ TANLo /ECS reached 67% (CI95% 52–86%;
P < 0.0001) conﬁrming the detrimental value of
the high CD66b+ TAN density in M-TDLNs
(Figure 3k).
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Figure 3. Clinical signiﬁcance of CD66b+ TANs in OSCC primary tumors (PTs) and TDLNs. Bar plots indicate the mean  SD percentage of alive
PMN after co-culture for 40 h with or without OSCC cell lines (SCC-4, n = 3; SCC-25, n = 2 or CAL-27, n = 2) (a). PMN negative for vibrant
staining were considered to be viable (see the Methods section); for conditioned media experiments, PMN were cultured for up to 40 h with or
without OSCC-derived conditioned media (SCC-4 n = 3, SCC-25 n = 3 or CAL-27 n = 3) in the presence or absence of 10 lg mL1 neutralising
human anti-GM-CSF Ab or anti-IL-6R Ab (b–d). In b, bar plots display the mean  SD percentage of alive PMN at 40 h; in c and d, bar plots
show the PMN mean  SD ﬂuorescence intensity (MFI) membrane expression of CD11b and CD62L, respectively, analysed at 20 h by ﬂow
cytometry; GM-CSF and IL-6 levels, as measured by ELISA, in cell-free supernatants collected from 2.5 9 106 mL1 neutrophils and
5 9 10 4 mL 1 OSCC cell lines cultured for up to 40 h (e); P-values were estimated by the one-way ANOVA followed by the Tukey’s correction
for pairwise comparisons (a–d) or by the unpaired t-test (e). Boxplots of CD66b+ TAN density in the OSCC PT compartments (f); P-values were
estimated by the Mann–Whitney U-test. Correlogram of CD66b+ TAN density correlations among different tumor areas, r values are shown and
ellipses show signiﬁcant results (P < 0.05, Spearman test) (g). Multivariable survival analysis (Overall Survival) graphs showing survival probability
at 5 years according to Stage I and II or III and IV and CD66b+ TAN density in the invasive margin (IM) (h) or in the centre of the tumor (CT) (i).
Heatmap showing the 5 years overall survival probability according to AJCC stage and CD66b+ TAN density in the CT, adjusted for CD66b + TAN
density in the IM (j). Heatmap showing the 2 years overall survival probability according to CD66b+ TAN density in the CT and CD66b + TAN
density in M-TDLNM, adjusted for ECS status (k). Multivariable survival analysis (Overall Survival) graph showing survival probability at 2 years
according to ECS status and CD66b + TAN density in M-TDLN M (l). Kaplan Meier curves of the univariate survival analysis according to the MTDLNM CD66b + TAN score (cut-off 163 cells mm2 ) showing subgroups of patients according to M-TDLNM CD66b + TAN score and ECS status
(m), all pairwise comparisons (Holm adjusted) showed signiﬁcant differences except between CD66b+ TAN M-TDLNM Hi ECS and CD66b + TAN
M-TDLNM Lo ECS + (P = 0.93).
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Table 1. Multivariable overall survival analysis of CD66b+ TANs in OSCC primary tumors and TDLNs
Wald statistics
Factor

Chi-square

d.f.

P

Factor

H.R. (95% C.I.)

15.96
7.98
6.84
6.16
6.06

3
2
2
1
1

0.0012
0.0185
0.0327
0.0130
0.0138

AJCC stage (Stage III-IV : Stage I-II)
TAN density CTa
TAN density IM a
TAN density CTb
TAN density IM b

2.98 (1.6–5.55)
0.42 (0.16–1.11)
1.53 (0.87–2.71)
1.59 (1.06–2.39)
0.63 (0.42–0.96)

0.72
1.42
1.95
2.01
16.77
11.03
4.41

1
1
1
1
2
2
1

0.3967
0.2327
0.1624
0.1561
0.0002
0.0040
0.0358

TAN density CT
TAN density IM
TAN density NM-TDLN
TAN density M-TDLN P
ECS+ : ECS-c
TAN density M-TDLN Mc
TAN density M-TDLNMd

1.27 (0.73–2.22)
0.68 (0.36–1.29)
1.3 (0.9–1.88)
0.77 (0.53–1.11)
2.48 (1.18–5.2)
1.22 (1–1.48)
2.19 (1.28–3.73)

CT, centre of the tumor; C.I., conﬁdence interval; d.f., degrees of freedom; ECS, extracapsular spread; H.R., hazard ratio; IM, invasive margin.
* Interaction.
a
Adjusted to Stage I-II, TAN density CT = 155; TAN density IM = 194.
b
Adjusted to Stage III-IV, TAN density CT = 155, TAN density IM = 194.
c
Adjusted to ECS-, TAN density M-TDLNM = 64.
d
Adjusted to ECS+, TAN density M-TDLNM = 64.

Stable TAN phenotype in OSCC
compartments
The current understanding of markers uniquely
associated with pro-tumor functions of human
TANs is very limited. Our clinical data on OSCC
highlight variability of TAN density in terms of
prognostic signiﬁcance, likely indicating the
existence of stage or regional functional TAN
subsets. We compared the expression of putative
PMN-MDSC markers in various PT and TDLN
compartments by using immunohistochemistry. In
addition, a new specialised CD66b + TAN subset
(referred as ‘hybrid TANs’) with anti-tumor
capabilities and a mixed phenotype (additional
expression of HLA-DR, CD14, CD206, CD86 and
CCR7) was recently reported in the early-stage
14,38
non-small-cell lung carcinoma.
We therefore
tested also for the presence of this subset. These
analyses were performed on TANs from PT earlystage OSCC cases with very good prognosis (for
markers of hybrid TANs), PT late-stage OSCC with
poor prognosis and their matched M-TDLNs (for
putative PMN-MDSC markers). CD66b+ TANs from
PT early-stage OSCC cases with very good
prognosis (n = 10) lacked nuclear morphology of
hybrid TANs (round to oval), maintaining nuclear
segmentation of canonical mature neutrophils as
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shown by DAPI stain (Figure 4a). In addition, by
double staining, co-expression of HLADR, CD14
and CD66b was only limited to HLADR +/CD14 +
macrophages
phagocytosing
CD66b+
TANs
(Figure 4b and c). Neutrophil phagocytosis was
also conﬁrmed by double staining of CD66b and
CD163 and CD68 (Figure 4d and inset). In
addition, TANs from late-stage OSCC PTs with
poor prognosis and their matched M-TDLNs
(Figure 4e–t) showed the same expression levels
of putative PMN-MDSC markers20,21 S100A9,
arginase-1, c/EBPb and pSTAT3 (n = 4). These
markers were also observed in CD66b + neutrophils
found in early-stage PTs and suppurative
lymphadenitis (Figure 4h, l, p, t; n = 3).
Together, these ﬁndings indicate that novel
biomarkers of clinical relevance are needed to
identify TAN subsets with distinct biological
properties.

CD66b+ TANs in M-TDLNs interact with T
cells
By using markers for lymphoid and dendritic cells,
we next analysed cell interactions between
CD66b+ TANs and immune cells in a set of MTDLNs (n = 9) positive for CD66b+ TANs. CD66b +
TANs frequently co-localise with CD3+, CD8+ T cells
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Multivariable model 1
AJCC stage
TAN density CT
TAN density IM
AJCC stage * TAN density CT
AJCC stage * TAN density IM
Multivariable model 2
TAN density CT
TAN density IM
TAN density NM-TDLN
TAN density M-TDLN P
ECS
TAN density M-TDLN M
TAN density M-TDLN M * ECS

Effects
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(a)

Figure 4. Analysis of the MDSC and hybrid TAN markers. Sections are from representative cases of primary tumors (PTs) and M-TDLNs at
different disease stage, as labelled. DAPI highlighting TANs morphology and markers of hybrid TANs (a–d) and of MDSCs (e–t) are shown. The
phenotype of neutrophils from suppurative lymphadenitis is shown as the control (h, l, p, t). CD66b+ TANs are negative of CD14 and HLA-DR;
occasionally, they are found within the cytoplasm of CD14+(b) and HLA-DR +(c) cells, co-expressing the macrophage marker CD163 (d). Sections
are from early-stage OSCC PT (n = 2) (a–e, i, m, q) and late-stage PT from the stomach (f), pancreas (j), lung (n) and OSCC (r) coupled with
their matched M-TDLNs (g, k, o, s); a suppurative lymphadenitis case from non-tumor-bearing patients is included as control (h, l, p, t). S100A9,
c/EBPb and pSTAT3 are also expressed on neoplastic cells and/or stromal cells. Sections are counterstained with haematoxylin. Original
magniﬁcation: 4009 (e–t, scale bar 50 lm); 600 9 (a, scale bar 33 lm). b–d are digitally resized to show phagocytosis.
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the T-cell proliferation and polarisation towards a
regulatory T-cell phenotype that dominates the
M-TDLNM compartment requires a complex
modulation that is likely independent of TANs.

TAN signature in OSCC correlates with an
EMT switch at the invasive margin of the PT
Our microscopic ﬁndings suggest that TANs
directly interact with cancer cells within lymphatic
vessels. Epithelial-to-mesenchymal transition (EMT)
promotes epithelial tumor spread and recent
observations suggest that neutrophils can
efﬁciently escort tumor cells from blood vessels to
metastatic tissues 40 and promote EMT.41–43
Remarkably, the EMT signature is enriched in the
basal and mesenchymal subtypes of OSCC,
representing an independent predictor of nodal
metastasis. 26,44 By analysing the TCGA-HNSC (The
Cancer Genome Atlas-Head and Neck Squamous
Cell Carcinoma) dataset containing 308 OSCC
cases, we found that a partial EMT signature
(Supplementary ﬁgure 10) correlates with a
signature of genes highly expressed by
neutrophils
(Supplementary
table 5).
The
neutrophil signature was obtained from previous
studies12,45,46 and validated using RNAseq analysis
of highly pure peripheral blood neutrophils (not
shown). Among top neutrophil-speciﬁc targets
more associated with an EMT signature, we found
TNFAIP6, MMP9, OLR1, MME, CXCR1, KCNJ15,
TNFRSF10C, FCGRB3, CEACAM8 and FPR2 to be
speciﬁc to PMNs, 10 Supplementary ﬁgure 11a and
Supplementary
table 6).
Remarkably,
this
association was consistent for many of these
targets also in early-stage OSCC (Supplementary
ﬁgure 11b, c and Supplementary table 6). Of
note, PMNs10 were signiﬁcantly enriched in basal
and mesenchymal subtypes of OSCC (Figure 6a
and b). Previous studies indicate a localisation of
the p-EMT program to tumor cells found at the
invasive margin (IM), indicating a contribution
from the tumor microenvironment, likely driven
by local availability of TGF-b from cancer
associated ﬁbroblasts.26,47 Remarkably, TANs at
the IM in OSCC also surround tumor areas
showing an EMT switch and lymphangiogenesis.
By triple
staining, this observation was
documented in a set of N+ OSCC cases (n = 10)
showing highly recurrent co-localisation of TANs
with PDPN+ ki-67+ proliferative lymphatics 48,49
around S100A9/PDPN+ cancer cells (Figure 6c–f),
a phenotype highly correlated with EMT.26
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and BDCA2+ plasmacytoid dendritic cells (PDCs).
While T cells are regularly found within the
metastatic nest (M-TDLNM) and in the surrounding
nodal parenchyma (M-TDLNP), PDCs are mainly
restricted to the M-TDLN P (Figure 5a). We
expanded this observation by enumerating cell
contacts between TANs and nodal CD3+ T cells,
using a recently designed image analysis
algorithm39 on double stained slides (see the
Methods for details; n = 9). These data conﬁrm
that a signiﬁcant fraction of CD66b+ TANs contact
T cells, particularly in the M-TDLNP (Figure 5b and
Supplementary ﬁgure 9a–d). Among T cells, a
fraction of CD3+ T cells interacting with CD66b+
TANs express CD8 (Figure 5b and Supplementary
ﬁgure 9e, f). We further explored TAN/T cell
interaction and, by triple staining performed in
M-TDLNs (n = 3), we detected conjugates of
CD66b+ TANs with CD3 + T cells and S100 +
interdigitating dendritic cells (Figure 5c and d) in
all cases. These ﬁndings indicate that functional
interactions of TANs with T cells might occur also
in M-TDLNs.
The occurrence of numerous cell contacts
between CD66b+ TANs and CD3+ T cells in MTDLNs (Figure 5b and Supplementary ﬁgure 9a, b)
prompted us to investigate the T-cell status in MTDLNs from the OSCC cohort. Most of T cells
interacting with CD66b+ TANs are negative for
activated caspase-3 in both M-TDLN compartments
(Supplementary ﬁgure 9c, d). We then tested the
proliferation index (by ki-67 expression) of nodal
T cells in M-TDLNs (Figure 5e –h). This analysis was
Lo
performed in CD66b+ TAN
(n = 10) good
Hi
+
prognosis and CD66b TAN
(n = 10) worse
prognosis
tumor
cases.
Dermatopathic
lymphadenitis (D-LD) (n = 10) samples served as a
control group. We found that the proliferation
index of CD3 + T cells in the M-TDLNM was
signiﬁcantly increased compare to M-TDLN P and
D-LD; of note, no differences were noted by subgrouping for TAN density (Figure 5e). We then
tested the T-regulatory phenotype using a triple
staining for CD66b, Foxp3 and CD3 (n = 10)
(Figure 5i–l). Again, the frequency of Foxp3+CD3+
regulatory T cells was increased in the M-TDLNM
compared to M-TDLNP and D-LD; no signiﬁcant
differences were noted with respect to TAN
density (Figure 5i). Sequential double staining for
ki-67, CD3 and Foxp3 conﬁrmed that the large
majority (72.2%) of proliferating T cells in the MTDLN M corresponded to Foxp3 regulatory T cells
(Figure 5m). In summary, these data suggest that
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Figure 5. TAN/T-cell interactions and TANs polarisation in TDLNs. Graphs illustrate the frequency of different immune cell types (a) and the
percentage of TANs interacting with T cells (b) in the metastatic nest (M-TDLNM, black bars/circles) and nodal parenchyma (M-TDLN P, white
bars/circles) M-TDLN compartments quantiﬁed by using a digital microscopy algorithm by ImageJ software. Section of M-TDLN from gastric
carcinoma illustrating a triple interaction between T cells, CD66b + TANs and S100 + interdigitating dendritic cells (c, d) in M-TDLNM (c) and MTDLNP (d) nodal compartments. The graphs illustrate the percentage of ki-67 +CD3 + proliferating T cells (e) and of foxp3+ CD3 + regulatory T cells
(h) based on counts performed on triple stains (f, g, j, k). The analysis has been performed in the metastatic nest (M-TDLNM, black circles, f, j)
and nodal parenchyma (M-TDLN P, white circles, g, k) compartments of M-TDLNs CD66b+ TANHi with worse prognosis (n = 10) compared with
CD66b+ TAN Lo with good prognosis (n = 10). As control group, dermatopathic lymphadenitis has been included (grey triangles, d–l). Boxplots
reporting median and interquartile ranges of proliferating ki-67 + T cells (%, h) and of foxp3 + regulatory T cells (%) (l) in M-TDLN M, M-TDLN P or
D-LD; P-values were estimated by the Kruskal–Wallis test and pairwise comparisons using the Dunn’s procedure with a Bonferroni correction for
multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). M-TDLNs shown are from OSCC cases (n = 4) (f, g, j, k, m) and
stained as labelled. In m, images are taken as snapshot (from Aperio Scanscope) of digitalised slides and resized (bottom panels). Green arrow
heads indicate ki-67+CD3 + foxp3+ T cells, and yellow arrow heads indicate ki-67 +CD3+foxp3  T cells. Sections are counterstained with
haematoxylin. Original magniﬁcation: 4009 (c, d, scale bar 50 lm), 600 9 (f, g, j, k, scale bar 33 lm).
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TAN modulate EMT signature in OSCC

DISCUSSION
By completing a large-scale analysis of human
carcinoma samples, this study identiﬁed that
CD66b+ TANs recurrently colonise TDLNs, and that
their high nodal density is associated with a
detrimental prognosis in advanced stages
squamous cell carcinomas (SCC). Based on direct
and indirect evidence, we surmise that TANs in
PTs and in TDLNs are major contributors in the
organisation and evolution of the nodal
metastatic niche, likely by modulating EMT. This
hypothesis requires additional analysis using
appropriate animal models for in vivo tracing and
modulation of TAN functions. Importantly, lymph
node metastasis can fuel distant metastasis in a
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signiﬁcant fraction of cancers,16,32 as also recently
demonstrated by molecular analysis,16 thus
supporting an additional role of TANs in
promoting systemic spread.
Similar to TANs in the PT, the TDLN cellular
counterpart
shows
a
segmented
nuclear
morphology and expresses a panel of neutrophilspeciﬁc molecules, including cytoplasmic granuleassociated molecules and CD10, conﬁrming their
neutrophil identity and a mature phenotype. 51 In
addition, at similar levels to the PT, the TANs in
TDLNs express recently identiﬁed putative PMNMDSC markers, including S100A9, arginase-1,
pSTAT3 and c/EBPb. It should be noted that this
phenotype is observed also in neutrophils from
suppurative lymphadenitis, indicating that coexpression of these markers by CD66b+ cells is
insufﬁcient to deﬁne a TAN phenotype. In
particular, a dense CD66b+ TAN inﬁltration was
identiﬁed in head and neck SCC, gastric and
pancreatic adenocarcinoma and transitional
bladder cancer. By contrast, breast carcinoma
TDLNs are largely devoid of CD66b + TANs. In
breast carcinoma, a lower CD66b+ TAN density
was also evident in the corresponding PT,
suggesting site- and tumor-speciﬁc differences
likely due to limited homing of the circulating
TAN precursors from the blood.
An important and novel ﬁnding of this study is
that CD66b+ TANs in the PT form conjugates with
cancer cells within lymphatic emboli. Accordingly,
they reproduce similar conjugates in the marginal
and intermediate sinuses of the corresponding
TDLNs, within micro-metastatic foci. TAN entry
into the TDLNs might occur via lymphatic vessels
from the PT or, alternatively, through the blood
circulation via high endothelial venules.52 Our
microscopic analysis supports the hypothesis that
TANs could enter the TDLN via the lymphatic
route with a potential role played by CXCL8, a
chemokine known to regulate TAN recruitment
and
angiogenesis
and
supporting
tumor
progression. 33,53,54 CD66b+ TANs are also found
within sinuses of non-metastatic TDLNs (this
study), suggesting that a steady lymphatic
circulation of TANs might establish the premetastatic niche as observed in distant sites.34,36,55
We hypothesise that TANs provide a survival
signal to tumor cells or other cells (i.e.
macrophages) co-existing in the nodal sinuses.
Bidirectional signals between cancer cells and
TANs might also result in the activation of TANs in
proximity of tumor emboli. 56,57 TANs facilitate
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We tested the hypotheses that this EMTimprinting is acquired by circulating neutrophils
from cancer patients. To this end, we
prospectively collected peripheral blood from
OSCC cases (n = 15) and matched controls (n = 13)
and tested for the PMN 10 signature. The clinical
and laboratory ﬁndings of this cohort are
reported
in
Supplementary
table 7
and
Supplementary ﬁgure 12. Of relevance, the
frequency of CD66b+ neutrophils, most of which
displayed a CD10+ mature phenotype, as well as
the neutrophil-to-lymphocyte ratio (NLR) were
signiﬁcantly increased in the OSCC group
(Supplementary ﬁgure 12). The latter observations
were consistent with our data collected from a
larger patient cohort. 50 By phenotypic analysis of
the circulating compartment of neutrophils, we
could not detect signiﬁcant differences for
activation markers (CD62L, CD16, CD11b, CD54 or
CD274), adhesion molecules (CD11c or CD11a) and
chemotactic receptors, (CCR7, CXCR1, CXCR2 or
C5aR), with the exception of a signiﬁcantly
increased expression of CXCR4 observed in the
OSCC group (Supplementary ﬁgure 13). By reverse
transcription quantitative PCR (RT-qPCR) analysis
of the PMN10 signature performed on total RNA
extracted from circulating neutrophils, we could
not detect signiﬁcant differences between the
OSCC and the control group. One exception was
MME (alias CD10), that was signiﬁcantly increased
in the OSCC group (Figure 6g). These ﬁndings
suggest that a full pro-EMT phenotype is likely
acquired by local interaction of cancer cells with
TANs.
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Figure 6. PMN signature in OSCC. (a) The heatmap shows the log2 RPKM values for the PMN signature genes grouped by Subtype annotation
(n = 171 OSCC samples from the TCGA with available annotation). Samples are ordered in increasing overall expression values within Subtypes.
(b) The boxplot of PMN score (computed using GSVA algorithm) separately for Subtype annotation. P values are estimated by a linear model and
pairwise multiple comparisons adjusted for multiple tests with the Tukey–Kramer method. (c–f) Sections are from three OSCC PT (d and f single
case) and stained as labelled. Sections are counterstained with haematoxylin. Original magniﬁcation: 1009 (scale bar 200 lm; c, d, f images on
the left), 2009 (scale bar 100 lm; e image on the left) and 4009 (scale bar 50 lm; c–f images on the right). (g) Dot plots show the mRNA
expression of the PMN10 in circulating neutrophils freshly isolated from HDs or OSCC patients, as evaluated by RT-qPCR. Gene expression is
shown as mean normalised expression (MNE) units after RPL32 mRNA normalisation (mean  SD). Each symbol stands for a single HD (open
circle; n = 13) or OSCC patient (black circle; n = 15). *P ≤ 0.05 by the unpaired t-test.
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To establish the clinical relevance of nodal TAN
inﬁltration, we performed a large-scale analysis of
CD66b+ TAN density on a cohort of OSCC samples.
In this cohort, high neutrophil count and NLR50
were associated with poor prognosis. Data on the
clinical relevance of CD66b+ TANs by IHC are
partially conﬂicting, mainly due to differences in
the
analysis
methods.
However,
recent
computational approaches on a pan-cancer study
revealed that TAN abundance represents a
predictor of poor outcome. 12 To minimise the
analytical biases in tissue monitoring, we strictly
adhered to recently introduced guidelines.66 We
used a highly speciﬁc marker and measured a
highly representative PT tissue area on whole
digitalised slide (105  71 mm 2). A signiﬁcant
interaction was observed between TAN density in
the CT and in the IM and tumor Stage. A higher
density in the CT was associated with worse
prognosis only in advanced stage III and IV,
whereas it predicted better prognosis in the
earlier stages I and II; an opposite effect is
observed for TAN density in the IM. Stagedependent and spatially oriented molecular
analysis of TAN are required to further expand
our knowledge on this ﬁnding. However, this
level of stage- and site-dependent functional
heterogeneity requires further investigation.
Among potential explanations, the existence of
different TAN subsets, as recently described67
supports the hypothesis of a dynamic change of
pro-tumor TAN localisation along with disease
progression.
Among
anti-tumor
TANs,
Eruslanov’s groups have recently reported a
specialised TAN subset with a hybrid phenotype
found in early-stage non-small-cell lung cancer
and associated with good prognosis. 14,38 As in
other studies on human lymph nodes, these cells
are found to express MHC-II molecules.68 We
could not identify a similar population in OSCC,
likely indicating that hybrid anti-tumor TANs are
primary site speciﬁc.
Our study identiﬁes a contribution of nodal
TANs in OSCC prognosis with a high TAN density
in the metastatic nests (M-TDLNM) predicting
worse overall survival. This might indicate that
nodal TANs can promote systemic spread, likely by
immune escape. We found that TANs in TDLNs
recurrently
interact
with
T
cells
and
interdigitating dendritic cells. Consistently, by
image analysis we found that in M-TDLN, T-cell
proliferation
and
polarisation
towards
a
regulatory phenotype was signiﬁcantly increased,
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tumor
cell
migration,
extravasation
and
subsequent invasion, thus fostering cancer cell
arrest and growth at the metastatic site. 33
Notably, a set of proteases released by activated
TANs has been implicated in the formation and
dissemination of tumor aggregates in form of
emboli.58 These ﬁndings support the hypothesis
that nodal TANs can promote cancer cell
extravasation from the lymphatic sinuses, as well
as their subsequent growth and invasion of the
nodal parenchyma.55 Since TAN density in the PT
and in the M-TDLN M is highly correlated, we
surmise that only TANs receiving the appropriate
imprinting signals in the PT can execute a prometastatic program in TDLNs.
Neutrophils are abundant in carcinomas showing
squamous histology (SCC) mainly due to cancer cell
intrinsic molecular traits such as SOX2 overexpression.22–25 The latter occurs in SCC from various
primary sites59 including OSCC. 59–61 Moreover, TANs
are known to foster squamous cell fate in murine
models.23 We found that OSCCs provide a signiﬁcant
survival and activation signal to TANs via GM-CSF
expression. Mechanistically, the expression of a set
of neutrophil genes is signiﬁcantly associated with a
partial EMT signature in OSCC. As recently proposed,
EMT in cancer cells enhances their capacity to
disseminate also via lymphatics,62 which is highly
relevant in terms of OSCC prognosis. Of note, EMT in
OSCC represents an independent predictor of nodal
metastasis and EMT-switched tumor cells localise to
the IM, an area also enriched with lymphatic
vessels.26,44,48 We found that the top ten neutrophilspeciﬁc genes associated with the pro-EMT signature
(referred as PMN10), are detected also in a subset of
early-stage OSCC and are enriched in the basal and
mesenchymal OSCC subtypes, typically associated
with an EMT switch.26,44 By the analysis of
peripheral blood of OSCC patients, we also
demonstrate that the expression of PMN10 is very
limited in circulating neutrophils, with only MME
(alias CD10) being over-expressed. By contrast, overexpression of CXCR4, a chemokine receptor relevant
in the neutrophil homeostasis,63 in EMT of OSCC64
and
in
neutrophil-mediated
pro-metastatic
function,65 occurs early in circulating neutrophils
from OSCC patients. Recent data on carcinomas
from different sites have proposed TANs as a
relevant player in promoting EMT.41–43 Multiple
ﬁndings from this study further strengthen this
observation supporting that a full pro-EMT
signature in OSCC is likely acquired at the TAN stage
within the tumor tissue.
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METHODS
Tissues
This part of the study was approved by the local IRB to WV
(WW-IMMUNOCANCERhum , NP-906). Formalin-ﬁxed parafﬁn
embedded (FFPE) tissue blocks used for this study were
retrieved from the tissue bank of the Department of
Pathology (ASST Spedali Civili di Brescia, Brescia, Italy).
Human tissues included human bone marrow, thymus,
spleen, tonsil, lymph node, small bowel and appendix. In
all, 278 metastatic (M-TDLNs) and 175 non-metastatic
tumor-draining lymph nodes (NM-TDLNs), obtained from a
total of 216 patients with primary carcinomas from
different primary sites (skin, head and neck, thyroid, breast,
lung, stomach, pancreas, colon, bladder and ovary) or
cutaneous melanoma (17 cases). Details of M-TDLNs
analysed are reported in Supplementary table 1. A total of
45 cases of primary melanoma (9 cases) and carcinoma from
various sites were selected for a comparative analysis with
M-TDLNs.

OSCC cohort
This part of the study was approved by the local IRB to WV
(H&N Cancer, NP-2066). The retrospective study population
included 182 histologically conﬁrmed cases of oral cavity
squamous cell cancer (OSCC) who underwent radical
surgical resection and neck dissection between 2000 and
2014 (Otorhinolaryngology Department, ASST Spedali Civili
di Brescia, Brescia, Italy). Patients with at least 12 months of
follow-up or earlier death or recurrence were included.
Salvage surgery, metastatic disease, immunological
disorders or prior systemic treatment for malignancy
represented exclusion criteria. Patients were regularly
followed with clinical examinations and neck MRI or CT

every 3–6 months. Details of the cohort are reported in
Supplementary table 2. A prospective cohort, enrolled
between June 2014 and December 2014, included patients
affected by head and neck SCC, that underwent pretreatment full blood collection for ﬂow cytometry analysis
and reverse transcription quantitative real-time PCR
analysis; immunological disorders or prior systemic
treatment for malignancy represented exclusion criteria.

Immunohistochemistry
Four-micron thick FFPE sections were used for
immunohistochemical staining. The primary antibodies for
this study are listed in the Supplementary table 8. The
antibody used to detect granulocytes/TANs is CD66b diluted
1:200, clone G10F5, from BioLegend (San Diego, CA). The
reaction was revealed by Novolink Polymer (Leica
Microsystems, Wetzlar, Germany) followed by DAB. For
double immunohistochemistry, after completing the ﬁrst
immune reaction, the second was visualised using Mach 4
MR-AP (Biocare Medical, Concord, CA), followed by Ferangi
Blue (Biocare Medical) or New Fucsin (Agilent Technologies,
Santa
Clara,
CA)
as
chromogen.
For
triple
immunohistochemistry, after completing the second
immune reaction, the third was visualised using a
biotinylated system (Agilent) followed by AP-streptavidin
and New Fucsin as chromogen. Sections were then
counterstained with haematoxylin.
For the screening cohort, a training set of 15 cases on
digitalised slides (IHC nuclear algorithm, Aperio Scanscope,
Leica Microsystems) was used to deﬁne a three-tiered score
for CD66b + TANs as it follows: S0 = ≤ 20 cell mm2 (mean
12); S1 = ≤ 100 cells mm2 (mean 59); S2 = > 100 cells mm2
(mean 235). Neutrophils interactions with PDCs and T cells
were analysed using a speciﬁcally designed algorithm in
Image J by processing 10 captured high power ﬁeld on
CD66b/BDCA2, CD66b/CD3 and CD66b/CD8 double stained
sections. Enumeration of proliferating (CD66b, CD3 and ki67) and of regulatory (CD66b, CD3 and foxp3) T cells was
performed by using ImageScope (Aperio Counter Tool) on
triple stained sections of 20 M-TDLN cases from the OSCC
cohort. Control cases were represented by six dermatopatic
lymphadenitis.
For double sequential immunostains, the ﬁrst reaction is
deleted after ﬁrst chromogen de-stain and stripping. Anti-ki67 was used for the ﬁrst immune reaction, revealed using
Novolink
Polymer
and
developed
in
3-amino-9ethylcarbazole chromogen (AEC), counterstained with
haematoxylin and cover-slipped using gelatin. Subsequently,
the slides were digitally scanned, using Aperio Scanscope CS
(Leica Microsystems). After cover slip removal AEC was
washed out and the slides were eluted using a 2Mercaptoethanol/SDS solution (20 mL 10% w/v SDS with
12.5 mL 0.5 M Tris-HCl, pH6.8, 67.5 mL distilled water and
0.8 mL 2-ME). Slides were subsequently incubated in this
solution in a water-bath pre-heated at 56°C for 30 min.
Sections were washed for 1 h in distilled water. After
unmasking in microwave, anti-foxp3 was revealed using Raton-Mouse
HRP
polymer
(Biocare
Medical)
and
3.30 Diaminobenzidine. CD3 was revealed using Mach 4 MRAP and Ferangi blue as chromogen and slides were
counterstained with haematoxylin, cover-slipped and
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but not affected by a higher TAN density.
Notably, we also found that TANs interact with
nodal PDCs, a major source of type I IFN in human
lymph nodes. 69 This ﬁnding might suggest that
polarisation to N1 TANs via type I IFN10 could
occur 67 and likely be obtained by TLR8 or TLR9
agonists
(Clinicaltrials.gov
study
identiﬁers:
NCT02644967,
NCT03445533,
NCT03052205,
NCT02521870, NCT03084640 and NCT0266877).
Overall, this study identiﬁes and characterises
the clinical relevance of a novel TAN compartment
in carcinomas, particularly in SCC. Microscopic
analysis and the clinical ﬁndings from the OSCC
cohort highlight the relevance and the plasticity
of TAN compartments in various disease stages
and their role in promoting EMT. Tailored site
and stage-dependent modulation of TANs from
various compartments should be considered to be
therapeutic option for carcinoma patients and in
particular SCC.

Tumor-associated neutrophils in human carcinoma-draining lymph nodes

digitally scanned. The two digital slides were processed using
ImageScope. Slides were synchronised and corresponding
tissue regions were analysed using the counter tool.

Immunoscore deﬁnition by image analysis

Isolation of neutrophils
Circulating neutrophils were isolated by density gradient
centrifugation (Ficoll-Paque; GE Healthcare Life Sciences,
Marlborough, MA) of whole blood collected in BD Vacutainer
tubes with K2EDTA (BD Biosciences, Franklin Lakes, NJ) from
patients with OSCC or HDs or from buffy coats of healthy donors
and further puriﬁed (approximately 99.7% purity) by negative
selection using the EasySep neutrophil enrichment kit (StemCell
Technologies, Vancouver, Canada) as previously described.711
Human samples were obtained following informed, written,
consent by healthy donors, in accordance with the Declaration
of Helsinki. This study was carried out in accordance with the
recommendations of Ethic Committee of the Azienda
Ospedaliera Universitaria Integrata di Verona (Italy).

Cell cultures
Human oral squamous cell carcinoma (OSCC) cell lines, CAL27 (DSMZ n° ACC 446), SCC-4 (DSMZ n° ACC 618), SCC-25
(DSMZ n° ACC 617), were purchased from Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell
Cultures GmbH (DMSZ, Braunschweig, Germany). CAL-27
cell line was expanded in Dulbecco’s modiﬁed Eagle
medium (DMEM)(Corning, NY) at 37°C/5% CO2 , while SCC25 and SCC-4 cell lines were expanded in DMEM:Ham’s F12
(Euroclone, Pero, Milan, Italy) at a 1:1 ratio. All tissue
culture media were supplemented with 10% FBS (< 0.5 EU
per mL endotoxin, BioWhittaker-Lonza, Basel, Switzerland)
and 1% of penicillin/streptomycin (pen/strep) (Corning).

Neutrophils co-culture with OSCC cell lines
Co-culture experiments were performed in 24-well culture
plates (Corning) at 37°C/5% CO2 . Cell lines were plated at
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5 9 104 mL1 in RPMI (10% FBS, 1% P/S) 24 h prior the
addition of neutrophils, to permit their adhesion to the
plates. After the isolation, neutrophils were then suspended
at 0.25 and 2.5 9 106 mL1 in RPMI 1640 medium
(Corning), containing 10% FBS and 1% of pen/strep and
they were either plated alone, or directly added to the cell
lines (at neutrophil:cell line ratios of 5:1 and 50:1), to be
cultured for up to 40 h.
At the end of the incubation time, neutrophils were
detached from the co-cultures by gently pipetting, then
centrifuged at 300 9 g for 5 min and ﬁnally suspended in
50 lL phosphate-buffered saline (PBS) at 1 9 106 mL1
containing 2% FBS and 15 mm EDTA for ﬂow cytometry
assays.

Conditioned media experiments
Neutrophil were suspended in RPMI (10% FBS, 1% P/S) or
conditioned media harvested from OSCC cell lines (CAL-27,
SCC-4, SCC-25) plated at 5 9 10 6 mL1 in 96-well culture
plates (Corning) and then cultured for up to 40 h. Cytokine
blocking experiments were conducted by culturing
neutrophils in OSCC-derived conditioned media, previously
pre-incubated for 30 min at 37°C in the presence of speciﬁc
neutralising monoclonal antibodies (mAb) towards GM-CSF
(10 lg mL1 , R&D Systems, Minneapolis, MN). Alternatively,
neutrophils were pre-incubated with IL-6R (10 lg mL 1 for
30 min, R&D Systems). After the incubation, neutrophils
were then centrifuged at 300 9 g for 5 min and ﬁnally
suspended in 50 µL phosphatase-buffered saline (PBS) at
1 9 106 mL1 containing 2% FBS and 2 mm EDTA for ﬂow
cytometry assays.

Flow cytometry
Neutrophils were incubated with 5% human serum
(BioWhittaker-Lonza) for 5 min on ice and then stained for
30 min at 4°C using the following anti-human
ﬂuorochrome-conjugated mAbs or speciﬁc isotype controls
listed in Supplementary table 8. For immunophenotypic
characterisation of neutrophils from HD or OSCC patients,
events were acquired on an eight-colour three-laserMACSQuant Analyzer (Miltenyi Biotec, Bergish Gladbach,
Germany) while for co-culture and conditioned media
experiments, ﬂow cytometry was performed by the use of a
FACS MACSQuant Analyzer 16 Flow Cytometer (Miltenyi
Biotec). Neutrophils were identiﬁed on the basis of their
morphological parameters (forward scatter/side scatter) and
the CD66b expression. Phenotypic analysis was performed
on live cells, identiﬁed as Vybrant-negative (Vybrant
DyeCycleTM Violet; Life Technologies, Waltham, MA) or
propidium iodide (Life Technologies) negative cells. Cell
viability was deﬁned as the percentage of cells that were
negative for vibrant staining.
Data analysis was performed by using FlowJo software
(Tree Star). The median ﬂuorescence intensity (MFI) relative
to each molecule was obtained by subtracting either the
MFI of the correspondent isotype control or cell
autoﬂuorescence. Unpaired t-tests or one-way ANOVA
analysis were performed, as appropriate.
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Stained slides were acquired using a ScanScope digital
scanner. Images were viewed and organised using
ImageScope software. Each scanned image was annotated
manually and IHC Nuclear Image Analysis algorithm was
chosen for the analysis. Areas of suppurative necrosis were
excluded from the count. Data are expressed as number of
CD66b+ cells per mm2. In the primary tumor (PT), immune
cell density was measured either in the centre of the tumor
(CT) and in the invasive margin (IM). The invasive margin
was deﬁned as the tissue area of 1 mm wide from the front
of invasion of the tumor 700. For the analysis of tumordraining lymph nodes (TDLNs) at least one non-metastatic
TDLN (NM-TDLN) was analysed; in N + patients, slides
containing metastatic TDLN (M-TDLN) have been included.
The density of CD66b +TAN in M-TDLNs was counted in the
metastatic nests (M-TDLNM ) and surrounding lymph node
tissue (M-TDLNP ).

S Lonardi et al.

S Lonardi et al.

Tumor-associated neutrophils in human carcinoma-draining lymph nodes

Reverse transcription quantitative real-time
PCR (RT-qPCR)

Cytokines production
Cytokine concentrations in cell-free supernatants were
measured by commercially available ELISA kits, speciﬁc for
human IL-6 (Mabtech, Nacka Strand, Sweden) and GM-CSF
(BioLegend). Detection limits of these ELISA were as
follows: 10 pg mL1 for IL-6 and 7.8 pg mL 1 for GM-CSF.

Data preprocessing and statistical analysis
of the TCGA dataset
Raw counts for primary solid tumor samples were
downloaded from GDC portal harmonised repository using
TCGAbiolinks R/Bioconductor package (n = 528). FFPE
samples were removed, and only samples corresponding to
Oral Cavity anatomical area were kept (n = 308). Gene
differential expression was tested, after library size
normalisation based on TMM (the trimmed mean of Mvalues), using LIMMA linear modelling733 function were
used to model mean-variance relationship744. Single gene
expression used as biomarker was computed as log2-RPKM.
A global score for signature expression (either neutrophil or
pEMT) was computed using single sample enrichment based
on GSVA755 algorithm: single sample enrichment score
represents the degree to which the genes in a particular
gene set are coordinately up- or down-regulated within a
sample and were used as a global score for signature
expression. Hierarchical clustering was performed using
correlation based (Spearman) distance matrices and
complete agglomeration method.
A ﬁltering procedure to determine the PMN signature
genes most associated with pEMT signature was
performed based on two phases: ﬁrst we performed a
regularised Canonical Correlation Analysis (rCCA). This
multivariate statistical procedure serves to identify linear
combinations among variables between two datasets in
order to maximise their correlation. The (two) new sets of
canonical variates, constructed based on the original
datasets, determine a pair of canonical variates with a
maximised simple correlation. Each set of constructed
canonical variates are uncorrelated with each other.
Genes of both signatures are represented on a correlation
circle plot where coordinates represent the correlation
between each gene and the corresponding dimension.
The correlation between genes in the two signatures can
be visualised through the angles between two vectors
(from the origin to the gene): if the angle is sharp, the

Statistical analyses
Standard descriptive statistics were used for expressing
means, standard deviations and CV. The Mann–Whitney
U-test or the Kruskal–Wallis test was used for group
comparisons, as appropriate. Differences in CD66b +TAN
density among different areas were analysed using
nonparametric Spearman’s rank correlation. For survival
analysis, the overall survival (OS) was chosen as the endpoint. Univariate survival curves were estimated using the
Kaplan–Meier method and compared by the log-rank test.
Cut-off in continuous predictors was estimated using
maximally selected log-rank statistic. Multivariable
analyses were performed using Cox proportional hazard
models and expressed as hazard ratio (HR) with 95%
conﬁdence intervals (CI). To assess the clinical relevance
of inﬁltrating CD66b+ TANs in the PTs and lymph node
areas, we modelled immune cells densities as continuous
variables and their functional relationship with survival
outcomes were evaluated investigating interactions with
relevant clinical variables. In all the analysis, a signiﬁcance
level of 5% was used. GraphPad Prism Version 6.0 (San
Diego, CA) and R (version 3.5.1) were used for statistical
analysis.
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Immediately after puriﬁcation, total RNA (0.1 lg) was
extracted from 1 9 106 neutrophils by the RNeasy mini kit
(Qiagen, Venlo, Limburg, The Netherlands) and reverse
transcribed for RT-qPCR, performed as previously
described,722 utilising the gene-speciﬁc primer pairs (listed
in Supplementary table 9), all purchased from Thermo
Fisher Scientiﬁc). Data were calculated by Q-Gene software
(http://www.gene-quantification.de/download.html)
and
expressed as mean normalised expression (MNE) units, after
RPL32 normalisation.

correlation is positive, if the angle is obtuse the
correlation is negative and if the angle is right the
correlation is null. Therefore, PMN genes close to the
bulk of pEMT genes and far from the origin are likely to
be associated with the pEMT signature. In a second step
we performed simple linear regression of pEMT score
versus each PMN gene separately. PMN genes with a
positive coefﬁcient and signiﬁcant P-value (not adjusted),
were retained in the ﬁltering procedure. This was
performed for all samples and separately for low (I and
II) and high (III and IV) stage.
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